Background: The purpose of this study was to examine the efficacy and acceptability of an open-label conditioned placebo dose reduction (CPDR) treatment in 70 children with attention deficit hyperactivity disorder (ADHD). This paper focuses on the qualitative data from the study.
Methods: Following a double-blind, crossover dose finding procedure to determine each subject's optimal dose of stimulant medication, subjects were randomized to the CPDR treatment or one of two control groups. Outcome measures included parent and teacher ratings of ADHD behaviours and stimulant side effects. Qualitative assessments were based on open-ended interviews of children and parents. Positive responders to CPDR and controls were followed for 3 months to assess persistence of treatment benefits.
Results: Children randomized to CPDR showed an excellent treatment response, well maintained over time. Parents and children were generally accepting of the treatment. Most parents reported treatment benefits and 80% of the children found the placebo to be useful. Full disclosure of the placebo to parents and children did not appear to negate the placebo's effectiveness. Participation effects and changes in caregiver behaviour may have contributed to positive treatment outcomes.
Conclusions: Open-label use of placebos as part of CPDR treatment may represent an innovative, ethical way of harnessing the power of placebos in clinical therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2214.2007.00743.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Moxifloxacin-loaded PVA-chitosan composite films as potential ocular drug delivery systems: A comprehensive characterization and efficacy assessment.
Int J Biol Macromol
January 2025
Department of Pharmaceutics, School of Pharmacy, DRIEMS University, Tangi, Cuttack, Odisha, India. Electronic address:
To overcome the barriers often met by traditional ophthalmic formulations, polymeric films can be utilized as an alternative to enhance drug retention duration while managing medication release. In the current investigation, polymeric films made of poly (vinyl) alcohol (PVA) and chitosan (CS) loaded with Moxifloxacin Hydrochloride (M-HCl) and plasticized with Glutaraldehyde were formulated as potential ophthalmic delivery for the treatment of conjunctivitis. The thickness, surface pH, opacity, folding endurance, and % hemolysis were measured, followed by the transparency, microscopy, electrical conductivity, mechanical strength, swelling index, and invitro drug release studies.
View Article and Find Full Text PDFFrequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.
NPJ Precis Oncol
September 2024
Danish Cancer Institute, Copenhagen, Denmark.
We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain helicase DNA-binding protein 1 (CHD1) loss on prostate cancer tissue microarrays. We created CHD1-deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis.
View Article and Find Full Text PDFAR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
Oncogene
October 2024
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators of DNA damage repair (DDR) to potentially enhance therapeutic targeting of CRPC. Key findings demonstrate that CBP/p300 expression increases with disease progression and selects for poor prognosis in metastatic disease.
View Article and Find Full Text PDFGermline Mutations and Ancestry in Prostate Cancer.
Curr Oncol Rep
February 2024
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery at the Uniformed Services University of the Health Sciences, 6720A Rockledge Drive Suite 300, Bethesda, MD, 20817, USA.
Purpose Of Review: Prostate cancer is the most frequently diagnosed non-cutaneous malignancy of men in the USA; notably, the incidence is higher among men of African, followed by European and Asian ancestry. Germline mutations and, in particular, mutations in DNA damage repair genes (DDRGs) have been implicated in the pathogenesis of prostate cancer. This review intends to discuss the implication of ancestry on prostate cancer, specifically in regard to lack of diversity in genomic and genetic databases and the ability of providers to properly counsel patients on the significance of cancer genetic results.
View Article and Find Full Text PDFCorynoxine promotes TFEB/TFE3-mediated autophagy and alleviates Aβ pathology in Alzheimer's disease models.
Acta Pharmacol Sin
May 2024
Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research (CPDR), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Autophagy impairment is a key factor in Alzheimer's disease (AD) pathogenesis. TFEB (transcription factor EB) and TFE3 (transcription factor binding to IGHM enhancer 3) are nuclear transcription factors that regulate autophagy and lysosomal biogenesis. We previously showed that corynoxine (Cory), a Chinese medicine compound, protects neurons from Parkinson's disease (PD) by activating autophagy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!